6.4 Fibrinolytic System, Natural Anticoagulants & Thrombophilia

Fibrinolytic System, Natural Anticoagulants & Thrombophilia

Hemostasis is governed by a dynamic, exquisitely balanced equilibrium between procoagulant forces (driving clot formation to prevent hemorrhage) and anticoagulant/fibrinolytic mechanisms (restricting clot propagation and dissolving fibrin to maintain vascular patency). Disruption of this physiological balance toward excessive clot formation results in thrombophilia (hypercoagulability), predisposing patients to life-threatening venous thromboembolism (VTE) and arterial thrombosis.

---

The Fibrinolytic System: Biochemistry & Regulation

Fibrinolysis is the enzymatic dissolution of the fibrin clot during wound healing. It is catalyzed by the serine protease Plasmin, which circulates as the inactive liver-synthesized proenzyme Plasminogen.

                                  [ FIBRINOLYTIC SYSTEM ]

           Endothelial Release of t-PA                         Renal / Tissue u-PA
                       │                                                │
                       └───────────────────────┬────────────────────────┘
                                               │
                       PAI-1 (Inhibits) ──►   ▼
                                         [ PLASMINOGEN ]
                                               │
                                               ▼ (Cleavage at Arg561-Val562)
                                          [ PLASMIN ] ◄── α2-Antiplasmin (Inactivates Free Plasmin)
                                               │
                   ┌───────────────────────────┴───────────────────────────┐
                   ▼                                                       ▼
         [ CROSSLINKED FIBRIN ]                                  [ FIBRINOGEN (Native) ]
                   │                                                       │
                   ▼                                                       ▼
          [ D-DIMER FRAGMENTS ]                                  [ FDPs: FRAGMENTS X, Y, D, E ]
      (Specific Marker of DIC, DVT, PE)                      (No D-Dimer; Primary Fibrinogenolysis)

1. Plasminogen Activation & Localization

• Plasminogen Structure: A 92-kDa single-chain glycoprotein containing five kringle domains. These kringle domains possess high-affinity lysine-binding sites that bind lysine residues on fibrin polymers, incorporating plasminogen directly into the developing clot matrix.
• Tissue Plasminogen Activator (t-PA): Synthesized and constitutively released by vascular endothelial cells. t-PA has low enzymatic activity in circulating blood but undergoes a dramatic 1,000-fold increase in catalytic efficiency upon binding fibrin. This ensures that plasmin generation is strictly confined to the fibrin clot surface rather than occurring free in circulating plasma.
• Urokinase-type Plasminogen Activator (u-PA): Synthesized by renal tubular epithelium, monocytes, and endothelial cells; lacks high fibrin specificity and operates primarily in pericellular tissue remodeling and extravascular fibrinolysis.

2. Actions of Plasmin: FDPs vs. D-Dimer

Plasmin is a broad-specificity serine protease that cleaves multiple peptide targets:

• Degradation of Native Fibrinogen (Primary Fibrinogenolysis): Plasmin sequentially cleaves the carboxy-terminal ends of the $A\alpha$ and $B\beta$ chains of native fibrinogen. Digestion proceeds through Fragment X (central E domain with two intact D domains), Fragment Y (one D domain and one E domain), and finally terminal Fragment D and Fragment E. These circulating fragments are termed Fibrinogen Degradation Products (FDPs). FDPs exert potent anticoagulant effects by competing with fibrinogen for thrombin binding and blocking platelet GPIIb/IIIa receptors.
• Degradation of Factor XIIIa-Crosslinked Fibrin (Secondary Fibrinolysis): When plasmin degrades a mature, crosslinked fibrin clot, the covalent $\varepsilon$-($\gamma$-glutamyl)-lysine bonds connecting adjacent D domains resist cleavage. Plasmin liberates D-Dimer fragments (specifically, two covalently crosslinked D domains bonded to a central E domain, or free $D\text{-}D$ dimers).
• Critical Diagnostic Distinction:
  • D-Dimer: Elevated exclusively when thrombin has converted fibrinogen to fibrin, Factor XIIIa has crosslinked the fibrin, and plasmin has degraded the crosslinked clot. D-Dimer is markedly elevated in Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Disseminated Intravascular Coagulation (DIC).
  • Primary Fibrinogenolysis: Occurs in systemic hyperplasmin states (e.g., severe hepatic cirrhosis, prostatic carcinoma surgeries releasing urokinase). Plasmin degrades uncrosslinked circulating fibrinogen and Factor V/VIII: FDPs are elevated, but D-Dimer is strictly NORMAL / NEGATIVE.

3. Fibrinolytic Inhibitors

• Plasminogen Activator Inhibitor-1 (PAI-1): A serpin secreted by endothelial cells, platelets, and adipose tissue that binds and inactivates t-PA and u-PA in a 1:1 stoichiometric complex.
• Alpha-2-Antiplasmin ($\alpha_2$-AP): The primary, fast-acting physiological inhibitor of plasmin. It rapidly forms an irreversible, inactive complex with any free plasmin that escapes the fibrin clot into circulating plasma, preventing systemic lytic degradation of circulating fibrinogen and factors.
• Thrombin-Activatable Fibrinolysis Inhibitor (TAFI): A plasma carboxypeptidase activated by the thrombin-thrombomodulin complex. TAFI removes carboxy-terminal lysine and arginine residues from partially degraded fibrin, eliminating high-affinity binding sites for plasminogen and t-PA and attenuating clot lysis.

---

Natural Anticoagulant Systems

To prevent unchecked propagation of thrombosis beyond the site of vascular injury, the vascular system relies on three major natural anticoagulant pathways:

                               [ NATURAL ANTICOAGULANT PATHWAYS ]

  1. ANTITHROMBIN (AT) ──► Inhibits Thrombin (IIa), FXa, FIXa, FXIa, FXIIa
         ▲
         └── Heparan Sulfate / Heparin (Accelerates AT Activity by 1,000-fold)

  2. PROTEIN C / PROTEIN S PATHWAY
     Thrombin + Endothelial Thrombomodulin ──► Activates Protein C (APC)
                                                      │
     APC + Free Protein S (Cofactor) ◄────────────────┘
           │
           ▼ (Targeted Proteolytic Inactivation)
     Factor Va  ──► FVa Inactivated (Cleaved at Arg506 / Arg306)
     Factor VIIIa ──► FVIIIa Inactivated (Cleaved at Arg336 / Arg562)

  3. TISSUE FACTOR PATHWAY INHIBITOR (TFPI)
     TFPI binds Factor Xa ──► TFPI:FXa Complex binds & inactivates TF:FVIIa

1. The Antithrombin (AT) Pathway

• Mechanism: Antithrombin (formerly ATIII) is a 58-kDa serine protease inhibitor (serpin) synthesized by hepatocytes. It forms stable, irreversible covalent suicide complexes with the active serine center of Thrombin (Factor IIa), Factor Xa, Factor IXa, Factor XIa, and Factor XIIa.
• Heparin Acceleration: In the baseline uncatalyzed state, AT neutralizes target proteases relatively slowly. Vascular endothelial cell-surface heparan sulfate proteoglycans (and exogenous unfractionated heparin / LMWH) contain a unique high-affinity pentasaccharide sequence. Binding of this pentasaccharide to AT induces an allosteric conformational shift (expelling the reactive center loop), accelerating the rate of Factor Xa and thrombin inactivation by 1,000-fold.

2. The Protein C & Protein S Anticoagulant Pathway

• Thrombomodulin Reversal of Thrombin: Vascular endothelial cells express Thrombomodulin (TM), an integral transmembrane glycoprotein. Circulating thrombin binds TM with high affinity ($K_d \approx 0.5\text{ nmol/L}$). This binding alters thrombin's active site conformation: thrombin loses its procoagulant properties (can no longer cleave fibrinogen or activate platelets) and converts into an activator of Protein C.
• Endothelial Protein C Receptor (EPCR): EPCR presents the vitamin K-dependent zymogen Protein C to the thrombin-TM complex, accelerating its cleavage to Activated Protein C (APC).
• Inactivation of Factors Va and VIIIa: APC dissociates from EPCR and binds its vitamin K-dependent cofactor Protein S on negatively charged phospholipid membranes. The APC:Protein S complex proteolytically cleaves the heavy chains of Factor Va (at Arg506 and Arg306) and Factor VIIIa (at Arg336 and Arg562), completely dismantling the prothrombinase and intrinsic tenase complexes.
• Protein S Binding Dynamics: In human plasma, Protein S circulates in two distinct forms:
  • Free Protein S (~40%): The functionally active cofactor for APC.
  • Bound Protein S (~60%): Complexed to the complement regulatory protein C4b-Binding Protein (C4b-BP); functionally inactive.
  • Inflammatory State Impact: C4b-BP is an acute-phase reactant. In severe systemic inflammation, elevated C4b-BP binds more Protein S, reducing free active Protein S and inducing an acquired hypercoagulable state.

3. Tissue Factor Pathway Inhibitor (TFPI)

• Synthesized primarily by microvascular endothelial cells (circulating bound to lipoproteins and stored in endothelial surfaces and platelets). It contains three tandem Kunitz-type inhibitory domains:
  1. Kunitz-2 domain binds and inhibits Factor Xa.
  2. The resulting TFPI:FXa complex utilizes its Kunitz-1 domain to bind and feedback-inhibit the TF:FVIIa complex, completely turning off the extrinsic initiation of coagulation.

---

Hereditary Thrombophilias

---

Acquired Thrombophilias: Antiphospholipid Syndrome (APS) & Lupus Anticoagulant

Antiphospholipid Syndrome (APS) is an acquired autoimmune multisystem disorder characterized by arterial and/or venous thrombosis and pregnancy morbidity (recurrent spontaneous miscarriages, fetal demise, severe preeclampsia) in the presence of persistent antiphospholipid antibodies (aPL).

The Three Diagnostic Antiphospholipid Antibodies

Per the revised Sapporo / Sydney international diagnostic criteria, at least one laboratory criterion must be positive on two or more occasions tested at least 12 weeks apart:

1. Lupus Anticoagulant (LA): Functional clot-based antibodies that interfere with phospholipid-dependent coagulation tests.
2. Anticardiolipin Antibodies (aCL): Solid-phase immunoassay (ELISA / chemiluminescence) detecting IgG or IgM isotypes at medium-to-high titers ($>40\text{ GPL or MPL units}$).
3. Anti-$\beta_2$-Glycoprotein I Antibodies (anti-$\beta_2$GPI): Solid-phase immunoassay detecting IgG or IgM directed against the domain I epitope of $\beta_2\text{GPI}$.

The Lupus Anticoagulant Laboratory Paradox & Three-Step Testing Protocol

• The In Vitro vs. In Vivo Paradox:
  • In Vitro (The Artifact): LA autoantibodies bind to phospholipid-protein complexes (such as $\beta_2\text{GPI}$ and prothrombin) in the test tube, sterically hindering the assembly of tenase and prothrombinase complexes on reagent phospholipids. This causes paradoxical prolongation of phospholipid-dependent clotting tests (aPTT, Dilute Russell's Viper Venom Time [dRVVT]).
  • In Vivo (The Pathology): In the patient, LA antibodies crosslink receptors on endothelial cells, platelets, and monocytes, inducing pro-inflammatory and prothrombotic signaling that drives severe venous and arterial thrombosis.

                               [ LUPUS ANTICOAGULANT 3-STEP PROTOCOL ]

  STEP 1: SCREENING TEST
  • Perform low-phospholipid clotting assay (dRVVT Screen or LA-sensitive aPTT)
  • Result: PROLONGED CLOTTING TIME (suggests presence of inhibitor)
                                           │
                                           ▼
  STEP 2: 1:1 MIXING STUDY
  • Mix Patient Plasma 1:1 with Normal Pooled Plasma (NPP)
  • Result: NO CORRECTION (Clotting time remains prolonged ──► Demonstrates Inhibitor, rules out factor deficiency)
                                           │
                                           ▼
  STEP 3: CONFIRMATORY TEST
  • Repeat assay in the presence of EXCESS PHOSPHOLIPIDS (Bilayer liposomes, Platelet Lysate, Hexagonal-phase PE)
  • Result: COMPLETE CORRECTION / SHORTENING OF CLOTTING TIME
  • Principle: Excess phospholipids neutralize circulating LA autoantibodies, confirming PHOSPHOLIPID DEPENDENCE.

• Dilute Russell's Viper Venom Time (dRVVT): The gold-standard assay for Lupus Anticoagulant testing because venom from Daboia russelii directly activates Factor X in the presence of $Ca^{2+}$ and phospholipids, completely bypassing Factors XII, XI, IX, VIII, and VII (rendering the test immune to intrinsic pathway factor deficiencies or contact factor inhibitors).